Cargando…

Safety and efficacy of sirolimus combined with endocrine therapy in patients with advanced hormone receptor-positive breast cancer and the exploration of biomarkers

BACKGROUND: We performed a retrospective study on the efficacy and safety of sirolimus (an mTOR inhibitor) in hormone receptor (HR)-positive advanced breast cancer and searched for biomarkers to predict its efficacy. METHODS: All patients with HR-positive metastatic breast cancer treated with siroli...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yi, Zongbi, Liu, Binliang, Sun, Xiaoying, Rong, Guohua, Wang, Wenna, Li, Hui, Guan, Xiuwen, Li, Lixi, Zhai, Jingtong, Li, Chunxiao, Qian, Haili, Ma, Fei, Xu, Binghe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7375615/ https://www.ncbi.nlm.nih.gov/pubmed/32335491 http://dx.doi.org/10.1016/j.breast.2020.04.004

Ejemplares similares

Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
por: Yi, Zongbi, et al.
Publicado: (2019)

Molecular landscape of TP53 mutations in breast cancer and their utility for predicting the response to HER‐targeted therapy in HER2 amplification‐positive and HER2 mutation‐positive amplification‐negative patients
por: Liu, Binliang, et al.
Publicado: (2022)

Molecular landscape and efficacy of HER2-targeted therapy in patients with HER2-mutated metastatic breast cancer
por: Yi, Zongbi, et al.
Publicado: (2020)

Landscape of somatic mutations in different subtypes of advanced breast cancer with circulating tumor DNA analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Gut Microbiota Profiling in Patients With HER2-Negative Metastatic Breast Cancer Receiving Metronomic Chemotherapy of Capecitabine Compared to Those Under Conventional Dosage
por: Guan, Xiuwen, et al.
Publicado: (2020)

The molecular tumor burden index as a response evaluation criterion in breast cancer
por: Yi, Zongbi, et al.
Publicado: (2021)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study
por: Liu, Binliang, et al.
Publicado: (2018)

Genome-wide chromosomal instability by cell-free DNA sequencing predicts survival in patients with metastatic breast cancer
por: Mo, Hongnan, et al.
Publicado: (2020)

Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer
por: Guan, Xiuwen, et al.
Publicado: (2021)

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

Clinical spectrum and prognostic value of TP53 mutations in circulating tumor DNA from breast cancer patients in China
por: Yi, Zongbi, et al.
Publicado: (2020)

The Efficacy and Safety of Programmed Cell Death 1 and Programmed Cell Death 1 Ligand Inhibitors for Advanced Melanoma: A Meta-Analysis of Clinical Trials Following the PRISMA Guidelines
por: Guan, Xiuwen, et al.
Publicado: (2016)

Plasma cell-free DNA and survival in non-small-cell lung cancer: A meta-analysis
por: Yi, Zongbi, et al.
Publicado: (2017)

Development and Validation of a New Clinical Prediction Model of Catheter-Related Thrombosis Based on Vascular Ultrasound Diagnosis in Cancer Patients
por: Liu, Binliang, et al.
Publicado: (2020)

Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells
por: Guan, Xiuwen, et al.
Publicado: (2016)

Breast Cancer in Chinese Females Aged 25 Years and Younger
por: Li, Lixi, et al.
Publicado: (2021)

Prognostic Factors and a Model for Occult Breast Cancer: A Population-Based Cohort Study
por: Zhang, Di, et al.
Publicado: (2022)

Mutational characteristics determined using circulating tumor DNA analysis in triple‐negative breast cancer patients with distant metastasis
por: Rong, Guohua, et al.
Publicado: (2020)

DNA damage response as a prognostic indicator in metastatic breast cancer via mutational analysis
por: Rong, Guohua, et al.
Publicado: (2021)

ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy
por: Ma, Fei, et al.
Publicado: (2016)

Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer
por: Yi, Zongbi, et al.
Publicado: (2017)

High SURF4 expression is associated with poor prognosis of breast cancer
por: Zhai, Jingtong, et al.
Publicado: (2022)

Tumor senescence leads to poor survival and therapeutic resistance in human breast cancer
por: Zhai, Jingtong, et al.
Publicado: (2023)

PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer
por: Guo, Fengzhu, et al.
Publicado: (2023)

Extracellular matrix-derived mechanical force governs breast cancer cell stemness and quiescence transition through integrin-DDR signaling
por: Li, Cong, et al.
Publicado: (2023)

Serum sodium ions and chloride ions associated with taxane-induced peripheral neuropathy in Chinese patients with early-stage breast cancer: A nation-wide multicenter study
por: Zhai, Jingtong, et al.
Publicado: (2022)

The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial–mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer
por: Guan, Xiuwen, et al.
Publicado: (2019)

The Effect of Tanreqing Injection on the Pharmacokinetics of Sirolimus in Rats
por: Zhang, Feng, et al.
Publicado: (2019)

Endocrine Therapy-Based Strategies for Metastatic Breast Cancer with Different Endocrine Sensitivity Statuses: A Systematic Review and Network Meta-Analysis
por: Wang, Jiani, et al.
Publicado: (2022)

Optimization of Initial Dose Regimen for Sirolimus in Pediatric Patients With Lymphangioma
por: Chen, Xiao, et al.
Publicado: (2021)

Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer
por: Mo, Hongnan, et al.
Publicado: (2022)

Sirolimus-induced pneumonitis
por: Singh, U., et al.
Publicado: (2009)

Lymphedema attributed to sirolimus
por: Ardalan, Mohammad-Reza
Publicado: (2013)

Hormone Production in Endocrine Tumours
por: Abelson, Denis
Publicado: (1958)

Hormone Regulation of CCCH Zinc Finger Proteins in Plants
por: Wang, Qiao, et al.
Publicado: (2022)

Amorphous Nanoparticulate Formulation of Sirolimus and Its Tablets
por: Shen, Yudong, et al.
Publicado: (2018)

Impact of Chemical Endocrine Disruptors and Hormone Modulators on the Endocrine System
por: Guarnotta, Valentina, et al.
Publicado: (2022)

Nanomedicines in renal transplant rejection – focus on sirolimus
por: Shen, Li-Jiuan, et al.
Publicado: (2007)

Transcriptomics analysis of sirolimus treatment in lupus nephritis
por: Wang, Dongdong, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pm3lk7dm2vfmnd4q8ljq65r944